

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Biocure Technology Inc. (the "Issuer").

Trading Symbol: CURE

Number of Outstanding Listed Securities: 96,937,001

Date: March 5, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Biocure Technology Inc.'s OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the United States.

Biocure Technology Inc. has arranged a non-brokered private placement of 6,976,745 units at 43 cents per unit for gross proceeds of \$3-million, or more, depending on investor interest. Each unit will entitle the holder to receive one common share of the company and one full warrant, exercisable for 24 months for 86 cents. Each warrant is subject to accelerated expiry provisions, such that if at any time after the expiry of any resale restriction governing the subscribed shares, the corporation's common shares trade on the Canadian Securities Exchange at or above a volume-weighted average trading price of \$1.29 per common share for 10 consecutive trading days, the company may give notice to the holders that each warrant will expire 30 days from the date of providing such notice. Finders' fees, or commissions, may be payable by the company in connection with this private placement.

Biocure Technology Inc.'s BiocurePharm Korea (BPK) entered into a memorandum of understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, the Republic of Uzbekistan (MHU) and Gold-Dream LLC (GDL) on Feb. 15, 2019, in Korea. The delegates from MHU visited the city of Daejeon, where BPK is located, for the signing of the MOU and a tour of the GMP (good manufacturing practice) facilities. The delegates also met with municipality officials from Daejeon. The main purpose of the MOU is to advance the discussions regarding a joint venture project in Uzbekistan to produce biopharmaceuticals, basic drugs and vaccines required for Uzbekistan people, as well as to further develop the pharmaceutical business in Uzbekistan. MHU is very interested in promoting and growing the pharmaceutical industry in its nation and would like to invite BPK and GDL to construct manufacturing facilities of pharmaceuticals with the investment of \$82-million (U.S.). GDL shall finance the project, whilst BPK is will supply the technology and the intellectual properties to produce the designated drugs and vaccines.

BiocurePharm Korea (BPK), a wholly owned Korean subsidiary of Biocure Technology Inc., has closed its non-brokered private placement. BPK has issued 96,404 shares at \$11.45 per share for gross proceeds of \$1,103,749. After the issuance of new BPK shares, Biocure now holds a 97.32-per-cent interest in BPK. The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.

2. Provide a general overview and discussion of the activities of management

Biocure Technology Inc.'s OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the United States.

Biocure Technology Inc. has arranged a non-brokered private placement of 6,976,745 units at 43 cents per unit for gross proceeds of \$3-million, or more, depending on investor interest. Each unit will entitle the holder to receive one common share of the company and one full warrant, exercisable for 24 months for 86 cents. Each warrant is subject to accelerated expiry provisions, such that if at any time after the expiry of any resale restriction governing the subscribed shares, the corporation's common shares trade on the Canadian Securities Exchange at or above a volume-weighted average trading price of \$1.29 per common share for 10 consecutive trading days, the company may give notice to the holders that each warrant will expire 30 days from the date of providing such notice. Finders' fees, or commissions, may be payable by the company in connection with this private placement.

Biocure Technology Inc.'s BiocurePharm Korea (BPK) entered into a memorandum of understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, the Republic of Uzbekistan (MHU) and Gold-Dream LLC (GDL) on Feb. 15, 2019, in Korea. The delegates from MHU visited the city of Daejeon, where BPK is located, for the signing of the MOU and a tour of the GMP (good manufacturing practice) facilities. The delegates also met with municipality officials from Daejeon. The main purpose of the MOU is to advance the discussions regarding a joint venture project in Uzbekistan to produce biopharmaceuticals, basic drugs and vaccines required for Uzbekistan people, as well as to further develop the pharmaceutical business in Uzbekistan. MHU is very interested in promoting and growing the pharmaceutical industry in its nation and would like to invite BPK and GDL to construct manufacturing facilities of pharmaceuticals with the investment of \$82-million (U.S.). GDL shall finance the project, whilst BPK is will supply the technology and the intellectual properties to produce the designated drugs and vaccines.

BiocurePharm Korea (BPK), a wholly owned Korean subsidiary of Biocure Technology Inc., has closed its non-brokered private placement. BPK has issued 96,404 shares at \$11.45 per share for gross proceeds of \$1,103,749. After the issuance of new BPK shares, Biocure now holds a 97.32-per-cent interest in BPK. The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable to the issuer during the month of February 2019

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the issuer during the month of February 2019

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Biocure Technology Inc.'s BiocurePharm Korea (BPK) entered into a memorandum of understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, the Republic of Uzbekistan (MHU) and Gold-Dream LLC (GDL) on Feb. 15, 2019, in Korea. The delegates from MHU visited the city of Daejeon, where BPK is located,

for the signing of the MOU and a tour of the GMP (good manufacturing practice) facilities. The delegates also met with municipality officials from Daejeon. The main purpose of the MOU is to advance the discussions regarding a joint venture project in Uzbekistan to produce biopharmaceuticals, basic drugs and vaccines required for Uzbekistan people, as well as to further develop the pharmaceutical business in Uzbekistan. MHU is very interested in promoting and growing the pharmaceutical industry in its nation and would like to invite BPK and GDL to construct manufacturing facilities of pharmaceuticals with the investment of \$82-million (U.S.). GDL shall finance the project, whilst BPK is will supply the technology and the intellectual properties to produce the designated drugs and vaccines.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the issuer during the month of February 2019

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..

Not applicable to the issuer during the month of February 2019

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the issuer during the month of February 2019

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the issuer during the month of February 2019

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable to the issuer during the month of February 2019

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable to the issuer during the month of February 2019

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the issuer during the month of February 2019

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Other than in relation to accounts payable incurred by the Issuer in the ordinary course of business with its service providers, not applicable to the issuer during the month of February 2019.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Shares BiocurePharm Korea	96,404	\$11.45 per share	General Working Capital

FORM 7 – MONTHLY PROGRESS REPORT

February 2019

Page 3

(1) *State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

Not applicable to the issuer during the month of February 2019

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the issuer during the month of February 2019

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable to the issuer during the month of February 2019

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 5th, 2019.

Konstantin Lichtenwald
Name of Director or Senior Officer

"Konstantin Lichtenwald"
Signature
CFO and Director
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		February 2019	YY/MM/D 19/03/05
BIOCURE TECHNOLOGY INC			
Issuer Address			
300-1055 West Hastings Street			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Vancouver BC, V6E 2E9	(604) 685 5120	(604) 609 7146	
Contact Name	Contact Position	Contact Telephone No.	
Konstantin Lichtenwald	Director	(604) 609 7146	
Contact Email Address	Web Site Address		
klichtenwald@bicuretech.com	www.biocuretech.com		